The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.

@article{Seandel2006TheAO,
  title={The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.},
  author={Marco Seandel and Jinru Shia and Irina Linkov and Robert G Maki and Cristina R Antonescu and J. -M. Dupont},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 20 Pt 1},
  pages={6203-4}
}
To the Editor: We read with great interest the work of Prenen et al. (1, 2), which revealed that the tyrosine kinase inhibitor sunitinib/SU11248 (Sutent; Pfizer, New York, NY), targeting KIT/CD117, vascular endothelial growth factor receptor (VEGF-R), platelet-derived growth factor receptor (PDGF-R), FLT3 (2), and possibly other cellular kinases (3), has clear in vitro efficacy against gastrointestinal stromal tumor (GIST) mutants refractory to imatinib mesylate (Gleevec; Novartis… CONTINUE READING